QUARTERLY REPORT

Q3 2025 — Form 10-Q

Q3 2025PDF · 43 pages417 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 27, 2025 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File Number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware 	04-2209186
(State or other jurisdiction of incorporation or organization) 	(I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol(s) 	Name of each exchange on which registered
Common Stock, $1.00 par value 	TMO 	New York Stock Exchange
3.200% Notes due 2026 	TMO 26B 	New York Stock Exchange
1.400% Notes due 2026 	TMO 26A 	New York Stock Exchange
1.450% Notes due 2027 	TMO 27 	New York Stock Exchange
1.750% Notes due 2027 	TMO 27B 	New York Stock Exchange
0.500% Notes due 2028 	TMO 28A 	New York Stock Exchange
1.375% Notes due 2028 	TMO 28 	New York Stock Exchange
1.950% Notes due 2029 	TMO 29 	New York Stock Exchange
0.875% Notes due 2031 	TMO 31 	New York Stock Exchange
2.375% Notes due 2032 	TMO 32 	New York Stock Exchange
3.650% Notes due 2034 	TMO 34 	New York Stock Exchange
2.875% Notes due 2037 	TMO 37 	New York Stock Exchange
1.500% Notes due 2039 	TMO 39 	New York Stock Exchange
1.875% Notes due 2049 	TMO 49 	New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2
of the Exchange Act.
Large accelerated filer ☒ 	Accelerated filer ☐ 	Non-accelerated filer ☐
Smaller reporting company ☐ 	Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of September 27, 2025, the Registrant had 375,708,059 shares of Common Stock outstanding.

-- 1 of 43 --

THERMO FISHER SCIENTIFIC INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 27, 2025
TABLE OF CONTENTS
Page
PART I - FINANCIAL INFORMATION
Item 1. 	Financial Statements (Unaudited) 	3
Condensed Consolidated Balance Sheets 	3
Condensed Consolidated Statements of Income 	4
Condensed Consolidated Statements of Comprehensive Income 	5
Condensed Consolidated Statements of Cash Flows 	6
Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity 	7
Notes to Condensed Consolidated Financial Statements 	9
Note 1. Nature of Operations and Summary of Significant Accounting Policies 	9
Note 2. Supplemental Balance Sheet Information 	10
Note 3. Debt and Other Financing Arrangements 	11
Note 4. Fair Value Measurements 	14
Note 5. Commitments and Contingencies 	15
Note 6. Supplemental Income Statement Information 	16
Note 7. Income Taxes 	18
Note 8. Comprehensive Income/(Loss) and Shareholders' Equity 	19
Note 9. Supplemental Cash Flow Information 	20
Note 10. Derivatives 	20
Note 11. Business Segment Information 	21
Note 12. Acquisitions 	26
Item 2. 	Management’s Discussion and Analysis of Financial Condition and Results of Operations 	28
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	36
Item 4. 	Controls and Procedures 	37
PART II - OTHER INFORMATION
Item 1. 	Legal Proceedings 	37
Item 1A. 	Risk Factors 	37
Item 2. 	Unregistered Sales of Equity Securities and Use of Proceeds 	37
Item 5. 	Other Information 	37
Item 6. 	Exhibits 	38
2

-- 2 of 43 --

THERMO FISHER SCIENTIFIC INC.
PART I FINANCIAL INFORMATION
Item 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
September 27, 	December 31,
(In millions except share and per share amounts) 	2025 	2024
Assets
Current assets:
Cash and cash equivalents 	$ 	1,982 	$ 	4,009
Short-term investments 	1,564 	1,561
Accounts receivable, less allowances of $155 and $173 	8,911 	8,191
Inventories 	5,745 	4,978
Contract assets, net 	1,620 	1,435
Other current assets 	2,472 	1,964
Total current assets 	22,295 	22,137
Property, plant and equipment, net 	10,177 	9,306
Acquisition-related intangible assets, net 	16,242 	15,533
Other assets 	5,019 	4,492
Goodwill 	49,287 	45,853
Total assets 	$ 	103,020 	$ 	97,321
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations 	$ 	3,823 	$ 	2,214
Accounts payable 	3,120 	3,079
Accrued payroll and employee benefits 	1,884 	1,988
Contract liabilities 	2,852 	2,852
Other accrued expenses 	3,209 	3,199
Total current liabilities 	14,888 	13,332
Deferred income taxes 	842 	1,268
Other long-term liabilities 	4,278 	3,989
Long-term obligations 	31,857 	29,061
Redeemable noncontrolling interest 	129 	120
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued 	— 	—
Common stock, $1 par value, 1,200,000,000 shares authorized; 444,644,993 and 443,841,240 shares issued 	445 	444
Capital in excess of par value 	18,330 	17,962
Retained earnings 	57,354 	53,102
Treasury stock at cost, 68,936,934 and 63,066,906 shares 	(22,310) 	(19,226)
Accumulated other comprehensive income/(loss) 	(2,801) 	(2,697)
Total Thermo Fisher Scientific Inc. shareholders’ equity 	51,018 	49,584
Noncontrolling interests 	7 	(33)
Total equity 	51,024 	49,551
Total liabilities, redeemable noncontrolling interest and equity 	$ 	103,020 	$ 	97,321
The accompanying notes are an integral part of these condensed consolidated financial statements.
3

-- 3 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(In millions except per share amounts) 	2025 	2024 	2025 	2024
Revenues
Product revenues 	$ 	6,489 $ 	6,148 $ 	18,719 $ 	18,266
Service revenues 	4,633 	4,450 	13,623 	13,218
Total revenues 	11,122 	10,598 	32,341 	31,484
Costs and operating expenses:
Cost of product revenues 	3,319 	3,170 	9,683 	9,189
Cost of service revenues 	3,220 	3,100 	9,431 	9,415
Selling, general and administrative expenses 	2,162 	2,098 	6,380 	6,392
Research and development expenses 	346 	346 	1,041 	1,016
Restructuring and other costs 	135 	45 	316 	151
Total costs and operating expenses 	9,182 	8,759 	26,850 	26,163
Operating income 	1,941 	1,838 	5,491 	5,321
Interest income 	234 	277 	735 	851
Interest expense 	(347) 	(356) 	(1,054) 	(1,073)
Other income/(expense) 	(2) 	(16) 	(18) 	(2)
Income before income taxes 	1,826 	1,742 	5,155 	5,096
Benefit from/(provision for) income taxes 	(207) 	(99) 	(394) 	(507)
Equity in earnings/(losses) of unconsolidated entities 	2 	(14) 	(9) 	(75)
Net income 	1,621 	1,629 	4,751 	4,514
Less: net income/(losses) attributable to noncontrolling interests and redeemable
noncontrolling interest 	5 	— 	11 	9
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,616 $ 	1,630 $ 	4,740 $ 	4,505
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic 	$ 	4.28 $ 	4.26 $ 	12.55 $ 	11.79
Diluted 	$ 	4.27 $ 	4.25 $ 	12.53 $ 	11.75
Weighted average shares
Basic 	378 	382 	378 	382
Diluted 	378 	384 	378 	383
The accompanying notes are an integral part of these condensed consolidated financial statements.
4

-- 4 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(In millions) 	2025 	2024 	2025 	2024
Comprehensive income/(loss)
Net income 	$ 	1,621 	1,629 $ 	4,751 $ 	4,514
Other comprehensive income/(loss):
Cumulative translation adjustment:
Cumulative translation adjustment (net of tax provision (benefit) of $46, $(244),
$(369) and $10) 	(17) 	(54) 	(104) 	748
Reclassification adjustment for losses included in net income 	6 	— 	6 	—
Unrealized gains/(losses) on available-for-sale debt securities:
Unrealized holding losses arising during the period (net of tax (provision) benefit of
$0, $0, $0 and $0) 	— 	— 	— 	(1)
Unrealized gains/(losses) on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax
(provision) benefit of $0, $0, $1 and $1) 	1 	1 	2 	2
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the
period (net of tax (provision) benefit of $(1), $2, $3 and $2) 	3 	(5) 	(8) 	(4)
Amortization of net loss included in net periodic pension cost (net of tax
(provision) benefit of $0, $0, $2 and $1) 	2 	— 	6 	2
Total other comprehensive income/(loss) 	(5) 	(58) 	(98) 	747
Comprehensive income/(loss) 	1,616 	1,572 	4,653 	5,261
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable
noncontrolling interest 	4 	6 	16 	9
Comprehensive income attributable to Thermo Fisher Scientific Inc. 	$ 	1,612 $ 	1,566 $ 	4,637 $ 	5,252
The accompanying notes are an integral part of these condensed consolidated financial statements.
5

-- 5 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Nine months ended
September 27, 	September 28,
(In millions) 	2025 	2024
Operating activities
Net income 	$ 	4,751 	$ 	4,514
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment 	758 	852
Amortization of acquisition-related intangible assets 	1,294 	1,514
Change in deferred income taxes 	(728) 	(1,007)
Stock-based compensation 	226 	222
Other net non-cash expenses 	315 	254
Changes in assets and liabilities, excluding the effects of acquisitions 	(2,255) 	(973)
Net cash provided by operating activities 	4,361 	5,377
Investing activities
Purchases of property, plant and equipment 	(1,060) 	(920)
Proceeds from sale of property, plant and equipment 	17 	40
Proceeds from cross-currency interest rate swap interest settlements 	218 	203
Acquisitions, net of cash acquired 	(4,037) 	(3,132)
Purchases of investments 	(351) 	(2,065)
Proceeds from sales and maturities of investments 	254 	9
Other investing activities, net 	20 	5
Net cash used in investing activities 	(4,938) 	(5,861)
Financing activities
Net proceeds from issuance of debt 	2,840 	1,204
Repayment of debt 	(1,625) 	(1,107)
Proceeds from issuance of commercial paper 	1,095 	—
Repayments of commercial paper 	(597) 	—
Purchases of company common stock 	(2,963) 	(3,000)
Dividends paid 	(474) 	(434)
Other financing activities, net 	(1) 	212
Net cash used in financing activities 	(1,725) 	(3,126)
Exchange rate effect on cash 	273 	182
Decrease in cash, cash equivalents and restricted cash 	(2,029) 	(3,427)
Cash, cash equivalents and restricted cash at beginning of period 	4,040 	8,097
Cash, cash equivalents and restricted cash at end of period 	$ 	2,011 	$ 	4,670
The accompanying notes are an integral part of these condensed consolidated financial statements.
6

-- 6 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Income/(Loss)
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity Noncontrolling
Interests Total Equity	(In millions) 	Shares 	Amount 	Shares 	Amount
Three months ended September 27, 2025
Balance at June 28, 2025 	$ 	126 	444 $ 	444 $ 18,232 $ 55,901 	67 $ (21,269) $ 	(2,797) $ 	50,512 $ 	(35) $ 50,476
Issuance of shares under stock
plans 	— 	— 	— 	28 	— 	— 	(32) 	— 	(5) 	— 	(5)
Stock-based compensation 	— 	— 	— 	70 	— 	— 	— 	— 	70 	— 	70
Purchases of company common
stock 	— 	— 	— 	— 	— 	2 	(1,000) 	— 	(1,000) 	— 	(1,000)
Dividends declared ($0.43 per
share) 	— 	— 	— 	— 	(163) 	— 	— 	— 	(163) 	— 	(163)
Net income/(loss) 	5 	— 	— 	— 	1,616 	— 	— 	— 	1,616 	1 	1,616
Other comprehensive
income/(loss) 	(1) 	— 	— 	— 	— 	— 	— 	(4) 	(4) 	— 	(4)
Contributions from (distributions
to) noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(9) 	— 	(9) 	— 	(9)
Disposition 	— 	— 	— 	— 	— 	— 	— 	— 	— 	42 	42
Balance at September 27, 2025 $ 	129 	445 $ 	445 $ 18,330 $ 57,354 	69 $ (22,310) $ 	(2,801) $ 	51,018 $ 	7 $ 51,024
Three months ended September 28, 2024
Balance at June 29, 2024 	$ 	115 	443 $ 	443 $ 17,649 $ 49,940 	61 $ (18,187) $ 	(2,413) $ 	47,432 $ 	(12) $ 47,419
Issuance of shares under stock
plans 	— 	1 	1 	115 	— 	— 	(40) 	— 	75 	— 	75
Stock-based compensation 	— 	— 	— 	68 	— 	— 	— 	— 	68 	— 	68
Dividends declared ($0.39 per
share) 	— 	— 	— 	— 	(149) 	— 	— 	— 	(149) 	— 	(149)
Net income/(loss) 	6 	— 	— 	— 	1,630 	— 	— 	— 	1,630 	(6) 	1,624
Other comprehensive
income/(loss) 	6 	— 	— 	— 	— 	— 	— 	(63) 	(63) 	(1) 	(64)
Contributions from (distributions
to) noncontrolling interests 	— 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	1 	— 	1 	— 	1
Balance at September 28, 2024 $ 	127 	444 $ 	444 $ 17,831 $ 51,421 	61 $ (18,227) $ 	(2,477) $ 	48,992 $ 	(20) $ 48,972
The accompanying notes are an integral part of these condensed consolidated financial statements.
7

-- 7 of 43 --

THERMO FISHER SCIENTIFIC INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY (Continued)
(Unaudited)
Redeemable
Noncontrolling
Interest
Common Stock 	Capital in
Excess of
Par Value
Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Income/(Loss)
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity
Noncontrolling
Interests Total Equity	(In millions) 	Shares 	Amount 	Shares 	Amount
Nine months ended September 27, 2025
Balance at December 31, 2024 	$ 	120 	444 $ 	444 $ 17,962 $ 53,102 	63 $ (19,226) $ 	(2,697) $ 	49,584 $ 	(33) $ 49,551
Issuance of shares under stock
plans 	— 	1 	1 	142 	— 	— 	(58) 	— 	85 	— 	85
Stock-based compensation 	— 	— 	— 	226 	— 	— 	— 	— 	226 	— 	226
Purchases of company common
stock 	— 	— 	— 	— 	— 	6 	(3,000) 	— 	(3,000) 	— 	(3,000)
Dividends declared ($1.29 per
share) 	— 	— 	— 	— 	(488) 	— 	— 	— 	(488) 	— 	(488)
Net income/(loss) 	13 	— 	— 	— 	4,740 	— 	— 	— 	4,740 	(1) 	4,738
Other comprehensive
income/(loss) 	5 	— 	— 	— 	— 	— 	— 	(103) 	(103) 	— 	(103)
Contributions from (distributions
to) noncontrolling interest 	(8) 	— 	— 	— 	— 	— 	— 	— 	— 	(2) 	(2)
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(26) 	— 	(26) 	— 	(26)
Disposition 	— 	— 	— 	— 	— 	— 	— 	— 	— 	42 	42
Balance at September 27, 2025 $ 	129 	445 $ 	445 $ 18,330 $ 57,354 	69 $ (22,310) $ 	(2,801) $ 	51,018 $ 	7 $ 51,024
Nine months ended September 28, 2024
Balance at December 31, 2023 	$ 	118 	442 $ 	442 $ 17,286 $ 47,364 	56 $ (15,133) $ 	(3,224) $ 	46,735 $ 	(11) $ 46,724
Issuance of shares under stock
plans 	— 	1 	1 	324 	— 	— 	(66) 	— 	259 	— 	259
Stock-based compensation 	— 	— 	— 	222 	— 	— 	— 	— 	222 	— 	222
Purchases of company common
stock 	— 	— 	— 	— 	— 	6 	(3,000) 	— 	(3,000) 	— 	(3,000)
Dividends declared ($1.17 per
share) 	— 	— 	— 	— 	(448) 	— 	— 	— 	(448) 	— 	(448)
Net income/(loss) 	16 	— 	— 	— 	4,505 	— 	— 	— 	4,505 	(7) 	4,498
Other comprehensive
income/(loss) 	— 	— 	— 	— 	— 	— 	— 	747 	747 	— 	747
Contributions from (distributions
to) noncontrolling interest 	(7) 	— 	— 	— 	— 	— 	— 	— 	— 	(1) 	(1)
Excise tax from stock repurchases 	— 	— 	— 	— 	— 	— 	(27) 	— 	(27) 	— 	(27)
Balance at September 28, 2024 $ 	127 	444 $ 	444 $ 17,831 $ 51,421 	61 $ (18,227) $ 	(2,477) $ 	48,992 $ 	(20) $ 48,972
The accompanying notes are an integral part of these condensed consolidated financial statements.
8

-- 8 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 1. Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life
sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and
manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare
and diagnostics.
Interim Financial Statements
The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management,
reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at September 27, 2025, the results of operations for the
three- and nine-month periods ended September 27, 2025 and September 28, 2024, and the cash flows for the nine-month periods ended September 27, 2025 and
September 28, 2024. Interim results are not necessarily indicative of results for a full year.
The condensed consolidated balance sheet presented as of December 31, 2024, has been derived from the audited consolidated financial statements as of that date.
The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the
annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in
conjunction with the 2024 financial statements and notes included in the company’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission (SEC). Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Note 1 to the consolidated financial statements for 2024 describes the significant accounting estimates and policies used in preparation of the consolidated financial
statements. There have been no material changes in the company’s significant accounting policies during the nine months ended September 27, 2025.
Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying unrounded amounts.
As a result, the sum of components may not equal corresponding totals due to rounding.
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of
revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and
businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on
the company's financial statements or disclosures.
Standard 	Description 	Adoption timing and approach
Impact of adoption
or other significant
matters
Standards recently adopted
ASU No. 2022-04, Liabilities-Supplier
Finance Programs (Subtopic 405-50):
Disclosure of Supplier Finance Program
Obligations
New guidance to disclose information about supplier finance
programs. Among other things, the new guidance requires expanded
disclosure about key program terms, payment terms, and amounts
outstanding for obligations under supplier finance programs for each
period presented.
Some aspects adopted in 2023 using a
retrospective method and other aspects
adopted in 2024 using a prospective
method
Not material
ASU No. 2023-07, Segment Reporting (Topic
280): Improving Reportable Segment
Disclosures
Among other things, new guidance to disclose significant segment
expenses and other items by reportable segment as well as
information about the chief operating decision maker.
2024 annual report and interim periods
thereafter using a retrospective method
Increased
disclosures in Note
11
9

-- 9 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Standard 	Description 	Adoption timing and approach
Impact of adoption
or other significant
matters
Standards not yet adopted
ASU No. 2023-09, Income Taxes (Topic
740): Improvements to Income Tax
Disclosures
Among other things, new guidance to disclose additional
information about the tax rate reconciliation and income taxes paid.
2025 annual report and interim periods
thereafter using a prospective method
Will increase
disclosures in Note
7
ASU No. 2024-03, Income Statement-
Reporting Comprehensive Income-Expense
Disaggregation Disclosures (Subtopic 220-
40): Disaggregation of Income Statement
Expenses
New guidance to disclose specified information about certain costs
and expenses.
2027 annual report and interim periods
thereafter using a prospective or
retrospective method
Will increase
disclosures in Note
6
ASU No. 2025-06, Intangibles-Goodwill and
Other-Internal-Use Software (Subtopic 350-
40): Targeted Improvements to the
Accounting for Internal-Use Software
Among other things, new guidance to modernize the accounting for
costs to develop software for internal use.
2028 annual report and interim periods
thereafter using a prospective,
retrospective, or modified transition
method; early adoption is permitted.
Currently evaluating
adoption impact,
timing, and method
Note 2. Supplemental Balance Sheet Information
Inventories
The components of inventories are as follows:
(In millions) 	September 27, 2025 	December 31, 2024
Raw materials 	$ 	1,984 	$ 	1,803
Work in process 	990 	755
Finished goods 	2,771 	2,420
Inventories 	$ 	5,745 	$ 	4,978
Contract-related Balances
Contract asset and liability balances are as follows:
(In millions) 	September 27, 2025 	December 31, 2024
Current contract assets, net 	$ 	1,620 	$ 	1,435
Noncurrent contract assets, net 	1 	6
Current contract liabilities 	2,852 	2,852
Noncurrent contract liabilities 	1,159 	1,138
In the three- and nine-month periods ended September 27, 2025, the company recognized revenues of $0.41 billion and $2.50 billion, respectively, that were
included in the contract liabilities balance at December 31, 2024. In the three- and nine-month periods ended September 28, 2024, the company recognized
revenues of $0.36 billion and $2.36 billion, respectively, that were included in the contract liabilities balance at December 31, 2023.
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of September 27, 2025, was
$26.46 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 53% of which is expected to occur
within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service
agreements, which typically have durations of three to five years.
10

-- 10 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 3. Debt and Other Financing Arrangements
The company’s debt and other financing arrangements are as follows:
Effective interest rate at
September 27, 	September 27, 	December 31,
(Dollars in millions) 	2025 	2025 	2024
Commercial Paper 	4.28 % $ 	500 	$ 	—
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 	— 	828
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 	— 	663
0.853% 3-Year Senior Notes, Due 10/20/2025 (Japanese yen-denominated) 	1.02 % 	149 	142
0.00% 4-Year Senior Notes, Due 11/18/2025 (euro-denominated) 	0.15 % 	644 	569
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 	3.36 % 	585 	518
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 	1.52 % 	819 	725
4.953% 3-Year Senior Notes, Due 8/10/2026 	5.18 % 	600 	600
0.832% 1.5-Year Senior Notes, Due 9/7/2026 (Swiss franc-denominated) 	1.13 % 	514 	—
5.00% 3-Year Senior Notes, Due 12/5/2026 	5.25 % 	1,000 	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 	1.66 % 	585 	518
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 	1.97 % 	702 	621
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated) 	1.18 % 	193 	184
4.80% 5-Year Senior Notes, Due 11/21/2027 	5.00 % 	600 	600
0.790% 3-Year Senior Notes, Due 1/6/2028 (Swiss franc-denominated) 	1.35 % 	110 	—
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 	0.77 % 	936 	828
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated) 	1.79 % 	414 	364
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated) 	0.90 % 	194 	184
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 	1.46 % 	702 	621
1.75% 7-Year Senior Notes, Due 10/15/2028 	1.89 % 	700 	700
5.00% 5-Year Senior Notes, Due 1/31/2029 	5.24 % 	1,000 	1,000
1.125% 4-Year Senior Notes, Due 3/7/2029 (Swiss franc-denominated) 	1.26 % 	395 	—
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 	2.08 % 	819 	725
2.60% 10-Year Senior Notes, Due 10/1/2029 	2.74 % 	900 	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated) 	1.44 % 	31 	30
1.120% 5-Year Senior Notes, Due 1/6/2030 (Swiss franc-denominated) 	1.25 % 	293 	—
4.977% 7-Year Senior Notes, Due 8/10/2030 	5.12 % 	750 	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 	0.89 % 	2,048 	1,812
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 	1.14 % 	1,053 	932
2.00% 10-Year Senior Notes, Due 10/15/2031 	2.23 % 	1,200 	1,200
1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated) 	1.92 % 	520 	457
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 	2.55 % 	702 	621
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated) 	1.60 % 	42 	40
4.95% 10-Year Senior Notes, Due 11/21/2032 	5.09 % 	600 	600
1.4175% 8-Year Senior Notes, Due 3/7/2033 (Swiss franc-denominated) 	1.49 % 	439 	—
5.086% 10-Year Senior Notes, Due 8/10/2033 	5.20 % 	1,000 	1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 	1.21 % 	1,755 	1,553
5.20% 10-Year Senior Notes, Due 1/31/2034 	5.34 % 	500 	500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 	3.76 % 	878 	777
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated) 	1.58 % 	144 	137
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated) 	2.10 % 	407 	358
1.520% 12-Year Senior Notes, Due 1/6/2037 (Swiss franc-denominated) 	1.56 % 	390 	—
11

-- 11 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Effective interest rate at
September 27, 	September 27, 	December 31,
(Dollars in millions) 	2025 	2025 	2024
1.6524% 12-Year Senior Notes, Due 3/6/2037 (Swiss franc-denominated) 	1.71 % 	269 	—
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 	2.94 % 	819 	725
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 	1.73 % 	1,053 	932
2.80% 20-Year Senior Notes, Due 10/15/2041 	2.90 % 	1,200 	1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 	1.78 % 	1,463 	1,294
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated) 	2.13 % 	98 	93
5.404% 20-Year Senior Notes, Due 8/10/2043 	5.50 % 	600 	600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated) 	2.06 % 	194 	184
5.30% 30-Year Senior Notes, Due 2/1/2044 	5.37 % 	400 	400
1.49% 20-Year Senior Notes, Due 1/6/2045 (Swiss franc-denominated) 	1.54 % 	232 	—
1.8975% 20-Year Senior Notes, Due 3/7/2045 (Swiss franc-denominated) 	1.95 % 	169 	—
4.10% 30-Year Senior Notes, Due 8/15/2047 	4.23 % 	750 	750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 	1.99 % 	1,170 	1,035
1.47% 25-Year Senior Notes, Due 1/6/2050 (Swiss franc-denominated) 	1.49 % 	410 	—
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 	2.07 % 	878 	777
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated) 	2.43 % 	223 	212
Other 	1 	73
Total borrowings at par value 	35,745 	31,332
Unamortized discount 	(95) 	(95)
Unamortized debt issuance costs 	(165) 	(164)
Total borrowings at carrying value 	35,484 	31,072
Finance lease liabilities 	196 	202
Less: Short-term obligations and current maturities 	3,823 	2,214
Long-term obligations 	$ 	31,857 	$ 	29,061
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt
issuance costs.
See Note 4 for fair value information pertaining to the company’s long-term borrowings.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The
Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), a Euro Interbank
Offered Rate (EURIBOR)-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement
contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a
Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the
company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other
obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter.
As of September 27, 2025, no borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.
12

-- 12 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program,
a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial
paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may
be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes
are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed
or floating basis.
Senior Notes
Interest is payable annually on the euro and public Swiss franc-denominated fixed rate senior notes and semi-annually on all other senior notes. Each of the U.S.
dollar and euro-denominated fixed rate senior notes, and Japanese yen-denominated and Swiss franc-denominated private placement notes may be redeemed at a
redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders
of the Japanese yen-denominated and Swiss franc-denominated private placement notes who have entered into cross-currency swap agreements. The company is
subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which
limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all
covenants related to its senior notes at September 27, 2025.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes
outstanding as of September 27, 2025, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due 2025,
the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has
fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt
securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-
01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt
securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are
consolidated in the financial statements of the company.
October 2025 Debt Issuances
In the fourth quarter of 2025, the company issued the following senior notes:
(In millions) 	Principal Value Issued
4.200% 5.5-Year Senior Notes due 3/1/2031 	$ 	500
4.473% 7-Year Senior Notes due 10/7/2032 	750
4.794% 10-Year Senior Notes due 10/7/2035 	750
4.894% 12-Year Senior Notes due 10/7/2037 	500
13

-- 13 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 4. Fair Value Measurements
Fair Value Measurements
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
September 27,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2025 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	162 	$ 	162 	$ 	— 	$ 	—
Bank time deposits 	1,560 	1,560 	— 	—
Investments 	87 	22 	— 	65
Insurance contracts 	277 	— 	277 	—
Derivative contracts 	415 	— 	415 	—
Contingent consideration 	65 	— 	— 	65
Total assets 	$ 	2,566 	$ 	1,744 	$ 	692 	$ 	129
Liabilities
Derivative contracts 	$ 	409 	$ 	— 	$ 	409 	$ 	—
Contingent consideration 	12 	— 	— 	12
Total liabilities 	$ 	421 	$ 	— 	$ 	409 	$ 	12
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 	2024 	(Level 1) 	(Level 2) 	(Level 3)
Assets
Cash equivalents 	$ 	1,103 	$ 	1,103 	$ 	— 	$ 	—
Bank time deposits 	1,560 	1,560 	— 	—
Investments 	39 	18 	— 	21
Insurance contracts 	240 	— 	240 	—
Derivative contracts 	460 	— 	460 	—
Total assets 	$ 	3,401 	$ 	2,680 	$ 	700 	$ 	21
Liabilities
Derivative contracts 	$ 	59 	$ 	— 	$ 	59 	$ 	—
Contingent consideration 	13 	— 	— 	13
Total liabilities 	$ 	72 	$ 	— 	$ 	59 	$ 	13
In the three- and nine-month periods ended September 27, 2025, the company recorded $8 million and $6 million, respectively, of net gains/(losses) on investments,
which are included in other income/(expense) in the accompanying statements of income. In the three- and nine-month periods ended September 28, 2024, the
company recorded $(4) million and $7 million, respectively, of net gains/(losses) on investments, which are included in other income/(expense) in the
accompanying statements of income.
The following table provides a rollforward of investments classified as level 3:
Three months ended 	Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024 	September 27, 2025 	September 28, 2024
Investments
Beginning balance 	$ 	59 	$ 	— 	$ 	21 	$ 	—
Purchases 	6 	26 	44 	26
Ending balance 	$ 	65 	$ 	26 	$ 	65 	$ 	26
14

-- 14 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of a qualifying transaction), of the contingent
consideration asset.
(In millions) 	2025
Contingent consideration asset
Beginning balance 	$ 	—
Acquisition 	65
Ending balance 	$ 	65
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as
well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration liabilities.
Three months ended 	Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024 	September 27, 2025 	September 28, 2024
Contingent consideration liabilities
Beginning balance 	$ 	5 	$ 	12 	$ 	13 	$ 	87
Acquisitions (including assumed balances) 	3 	— 	3 	—
Payments 	— 	— 	(6) 	(2)
Changes in fair value included in earnings 	4 	(4) 	3 	(78)
Ending balance 	$ 	12 	$ 	8 	$ 	12 	$ 	8
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
September 27, 2025 	December 31, 2024
(In millions) 	Carrying value 	Fair value 	Carrying value 	Fair value
Senior notes 	$ 	34,983 	$ 	32,573 	$ 	30,999 	$ 	28,454
Commercial paper 	500 	500 	— 	—
Other 	1 	1 	73 	73
$ 	35,484 	$ 	33,075 	$ 	31,072 	$ 	28,527
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the
company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally
developed pricing models and unobservable inputs, which represent level 3 measurements.
Note 5. Commitments and Contingencies
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential
costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup,
the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s
responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and
other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period
presented. At September 27, 2025, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2024
financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are
adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as
changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct
of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.
15

-- 15 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise
from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial
issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending
litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an
unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in the company’s 2024
financial statements and notes included in the company’s Annual Report on Form 10-K, nor are material losses deemed probable for such matters. It is reasonably
possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more such matters could have a material
adverse effect on the company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other
personal injury matters. At September 27, 2025, there have been no material changes to the accruals for pending product liability, workers compensation, and other
personal injury matters disclosed in the company’s 2024 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the
company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial
studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate
amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do
not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency
and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial
condition and ratings of its insurers on an ongoing basis.
Note 6. Supplemental Income Statement Information
Disaggregated Revenues
Revenues by type are as follows:
Three months ended 	Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024 	September 27, 2025 	September 28, 2024
Revenues
Consumables 	$ 	4,679 	$ 	4,379 	$ 	13,638 	$ 	13,070
Instruments 	1,811 	1,769 	5,080 	5,196
Services 	4,633 	4,450 	13,623 	13,218
Consolidated revenues 	$ 	11,122 	$ 	10,598 	$ 	32,341 	$ 	31,484
Revenues by geographic region based on customer location are as follows:
Three months ended 	Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024 	September 27, 2025 	September 28, 2024
Revenues
North America 	$ 	5,689 	$ 	5,591 	$ 	16,924 	$ 	16,640
Europe 	3,005 	2,686 	8,459 	7,968
Asia-Pacific 	2,013 	1,923 	5,824 	5,755
Other regions 	415 	397 	1,135 	1,122
Consolidated revenues 	$ 	11,122 	$ 	10,598 	$ 	32,341 	$ 	31,484
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions.
16

-- 16 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Revenues by business are as follows:
Three months ended 	Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024 	September 27, 2025 	September 28, 2024
Revenues
Biosciences 	$ 	1,023 	$ 	1,006 	$ 	3,091 	$ 	3,124
Genetic sciences 	720 	701 	2,076 	2,001
BioProduction 	817 	680 	2,234 	1,903
Other 	28 	(1) 	27 	(1)
Life Sciences Solutions 	2,588 	2,387 	7,428 	7,027
Chromatography and mass spectrometry 	841 	802 	2,398 	2,364
Chemical analysis 	320 	332 	898 	976
Electron microscopy 	732 	675 	2,043 	1,938
Analytical Instruments 	1,893 	1,808 	5,339 	5,277
Clinical diagnostics 	283 	266 	822 	802
ImmunoDiagnostics 	230 	212 	681 	649
Microbiology 	162 	159 	473 	471
Transplant diagnostics 	125 	114 	362 	332
Healthcare market channel 	444 	453 	1,325 	1,302
Elimination of intrasegment revenues 	(70) 	(75) 	(207) 	(200)
Specialty Diagnostics 	1,174 	1,129 	3,456 	3,355
Laboratory products 	594 	614 	1,776 	1,878
Research and safety market channel 	1,861 	1,739 	5,471 	5,225
Pharma services 	1,722 	1,647 	5,123 	4,852
Clinical research 	2,019 	1,956 	5,914 	5,938
Elimination of intrasegment revenues and other 	(226) 	(216) 	(679) 	(673)
Laboratory Products and Biopharma Services 	5,970 	5,740 	17,605 	17,221
Elimination of intersegment revenues 	(503) 	(467) 	(1,487) 	(1,397)
Consolidated revenues 	$ 	11,122 	$ 	10,598 	$ 	32,341 	$ 	31,484
Restructuring and Other Costs
In the first nine months of 2025, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort
to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2025, severance
actions associated with facility consolidations and cost reduction measures affected approximately 4% of the company’s workforce.
As of October 31, 2025, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment, that it expects will
result in additional charges of approximately $140 million, primarily in 2025 and 2026, and expects to identify additional actions in future periods.
Restructuring and other costs by segment are as follows:
Three months ended 	Nine months ended
(In millions) 	September 27, 2025 	September 27, 2025
Life Sciences Solutions 	$ 	78 	$ 	132
Analytical Instruments 	54 	68
Specialty Diagnostics 	— 	5
Laboratory Products and Biopharma Services 	39 	139
Corporate 	(36) 	(29)
$ 	135 	$ 	316
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying
balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.
17

-- 17 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(In millions) 	Total (a)
Balance at December 31, 2024 	$ 	50
Net restructuring charges incurred in 2025 (b) (c) 	161
Payments 	(127)
Currency translation 	1
Balance at September 27, 2025 	$ 	85
(a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b) Excludes $155 million of net charges, principally $91 million of charges for impairment of long-lived assets in the Life Sciences Solutions and Laboratory Products and
Biopharma Services segments.
(c) Excludes $51 million of net charges for disposition of a consolidated joint venture.
The company expects to pay accrued restructuring costs primarily through 2025.
Earnings per Share
The company’s earnings per share are as follows:
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(In millions except per share amounts) 	2025 	2024 	2025 	2024
Net income attributable to Thermo Fisher Scientific Inc. 	$ 	1,616 $ 	1,630 $ 	4,740 $ 	4,505
Basic weighted average shares 	378 	382 	378 	382
Plus effect of: stock options and restricted stock units 	1 	1 	1 	1
Diluted weighted average shares 	378 	384 	378 	383
Basic earnings per share 	$ 	4.28 $ 	4.26 $ 	12.55 $ 	11.79
Diluted earnings per share 	$ 	4.27 $ 	4.25 $ 	12.53 $ 	11.75
Antidilutive stock options excluded from diluted weighted average shares 	3 	2 	3 	2
Note 7. Income Taxes
The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to
income before provision for income taxes due to the following:
Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024
Statutory federal income tax rate 	21 % 	21 %
Provision for income taxes at statutory rate 	$ 	1,082 	$ 	1,070
Increases (decreases) resulting from:
Foreign rate differential 	(156) 	(93)
Income tax credits 	(180) 	(207)
Global intangible low-taxed income 	40 	90
Foreign-derived intangible income 	(86) 	(73)
Excess tax benefits from stock options and restricted stock units 	(7) 	(64)
Provision for (reversal of) tax reserves, net 	(31) 	216
Intra-entity transfers 	(153) 	(102)
Domestication transaction 	(125) 	—
Provision for (reversal of) valuation allowances, net 	(65) 	(161)
Tax return reassessments and settlements 	(5) 	(130)
Other, net 	80 	(38)
Provision for/(benefit from) income taxes 	$ 	394 	$ 	507
During the first quarter of 2025, the company recorded a deferred tax benefit of $125 million resulting from the recognition of a tax attribute related to a
domestication transaction. During the second quarter of 2025, the company recorded a deferred tax benefit of $153 million related to capital losses generated as part
of intra-entity transactions and a $93 million benefit in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income. During
the third quarter of 2025, the company recorded $86 million of tax benefits resulting from tax return reassessments.
18

-- 18 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
During the first nine months of 2024, the company recorded a tax reserve and associated interest of $240 million related to the settlement of international tax audits
for tax years 2009 through 2016, which were settled in the third quarter of 2024. The company also recorded tax benefits of $307 million, primarily in jurisdictions
where the deferred tax assets are now expected to be realized due to forecasted income. These benefits were partially offset by tax provisions primarily associated
with disallowed interest expense that is not expected to be realized.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S.
federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S.
federal statutory rate.
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted. The OBBBA includes a broad range of provisions, such as the permanent extension of
certain otherwise expiring provisions, modifications to the international tax framework and the reinstatement of favorable tax treatment for certain business
provisions. While most of the changes made by the OBBBA are effective in future tax years, some of its provisions are effective in 2025. There was no material
impact on the company’s effective tax rate. We will continue to monitor and assess the impact of OBBBA on our consolidated financial statements.
Unrecognized Tax Benefits
As of September 27, 2025, the company had $0.52 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate.
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions) 	2025
Balance at beginning of year 	$ 	525
Additions for tax positions of current year 	22
Reductions for tax positions of prior years 	(10)
Closure of tax years 	(19)
Settlements 	(3)
Balance at end of period 	$ 	515
Note 8. Comprehensive Income/(Loss) and Shareholders' Equity
Comprehensive Income/(Loss)
Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:
(In millions)
Cumulative
translation
adjustment
Unrealized
gains/(losses) on
hedging
instruments
Pension and
other
postretirement
benefit
liability
adjustment 	Total
Three months ended September 27, 2025
Balance at June 28, 2025 	$ 	(2,502) 	$ 	(24) 	$ 	(270) 	$ 	(2,797)
Other comprehensive income/(loss) before reclassifications 	(17) 	— 	3 	(14)
Amounts reclassified from accumulated other comprehensive income/(loss) 	7 	1 	2 	10
Net other comprehensive income/(loss) 	(10) 	1 	5 	(4)
Balance at September 27, 2025 	$ 	(2,512) 	$ 	(23) 	$ 	(265) 	$ 	(2,801)
Nine months ended September 27, 2025
Balance at December 31, 2024 	$ 	(2,409) 	$ 	(25) 	$ 	(263) 	$ 	(2,697)
Other comprehensive income/(loss) before reclassifications 	(104) 	— 	(8) 	(112)
Amounts reclassified from accumulated other comprehensive income/(loss) 	1 	2 	6 	9
Net other comprehensive income/(loss) 	(103) 	2 	(2) 	(103)
Balance at September 27, 2025 	$ 	(2,512) 	$ 	(23) 	$ 	(265) 	$ 	(2,801)
19

-- 19 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 9. Supplemental Cash Flow Information
Supplemental cash flow information is as follows:
Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment 	$ 	163 	$ 	190
Declared but unpaid dividends 	164 	151
Issuance of stock upon vesting of restricted stock units 	161 	183
Excise tax from stock repurchases 	26 	27
Unsettled share repurchases 	37 	—
Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:
(In millions) 	September 27, 2025 	December 31, 2024
Cash and cash equivalents 	$ 	1,982 	$ 	4,009
Restricted cash included in other current assets 	7 	10
Restricted cash included in other assets 	22 	21
Cash, cash equivalents and restricted cash 	$ 	2,011 	$ 	4,040
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees, pension related deposits, and incoming cash in China awaiting
government administrative clearance.
Note 10. Derivatives
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
(In millions) 	September 27, 2025 	December 31, 2024
Notional amount
Cross-currency interest rate swaps designated as net investment hedge - euro 	$ 	1,000 	$ 	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 	4,650 	4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 	2,500 	2,500
Currency exchange contracts 	1,462 	1,588
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance
sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.
Fair value – assets 	Fair value – liabilities
September 27, 	December 31, 	September 27, 	December 31,
(In millions) 	2025 	2024 	2025 	2024
Derivatives designated as hedging instruments
Cross-currency interest rate swaps 	$ 	413 	$ 	458 	$ 	408 	$ 	57
Derivatives not designated as hedging instruments
Currency exchange contracts 	2 	2 	1 	2
Total derivatives 	$ 	415 	$ 	460 	$ 	409 	$ 	59
The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheets under the caption other current assets, other assets, other
current liabilities, or other long-term liabilities. The fair value of currency exchange contracts is included in the accompanying balance sheets under the captions
other current assets or other accrued expenses.
20

-- 20 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Gain/(loss) recognized
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(In millions) 	2025 	2024 	2025 	2024
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive income/(loss)
to interest expense 	$ 	(1) 	$ 	(1) 	$ 	(3) 	$ 	(3)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in cumulative translation adjustment within other comprehensive
income/(loss) 	13 	(488) 	(1,225) 	(127)
Cross-currency interest rate swaps
Included in cumulative translation adjustment within other comprehensive
income/(loss) 	239 	(566) 	(395) 	171
Included in interest expense 	67 	67 	201 	200
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues 	(1) 	(6) 	(3) 	1
Included in other income/(expense) 	30 	15 	43 	5
Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the corresponding, offsetting
losses and gains on the underlying hedged transactions.
See Note 1 to the consolidated financial statements for 2024 included in the company’s Annual Report on Form 10-K for additional information on the company’s
risk management objectives and strategies.
Note 11. Business Segment Information
Business Segment Information
The company’s financial performance is reported in four segments. During 2025, there have been no changes to the company’s basis of segmentation or in the basis
of measurement of segment income. Other segment items included in the below tables consist of stock-based compensation and other incentive compensation
expenses, allocations of corporate expenses and certain overhead expenses as well as elimination of intersegment and intrasegment profits. Prior period segment
expense amounts have been recast to reflect the method for allocating expenses to segments in the current period.
21

-- 21 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2025
Three months ended September 27, 2025
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	2,194 $ 	1,847 $ 	1,154 $ 	5,927 $ 	11,122
Intersegment revenues 	394 	46 	20 	43 	503
2,588 	1,893 	1,174 	5,970 	11,626
Elimination of intersegment revenues 	(503)
Consolidated revenues 	$ 	11,122
Segment Income
Cost of revenues 	961 	975 	682 	4,622
Selling, general, and administrative expenses 	470 	307 	175 	582
Research and development expenses 	136 	144 	42 	14
Other segment items 	53 	39 	(46) 	(116)
Segment income 	968 	429 	321 	868 	2,587
Unallocated amounts
Cost of revenues adjustments 	(10)
Selling, general and administrative expenses adjustments 	(66)
Restructuring and other costs 	(135)
Amortization of acquisition-related intangible assets 	(435)
Interest income 	234
Interest expense 	(347)
Other income/(expense) 	(2)
Consolidated income before income taxes 	$ 	1,826
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	88,209 $ 	3,552 $ 	3,189 $ 	1,307 $ 	6,763 $ 	103,020
Purchases of property, plant and equipment 	23 	32 	18 	34 	297 	404
Depreciation of property, plant and equipment 	— 	62 	26 	23 	115 	227
22

-- 22 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2024
Three months ended September 28, 2024
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	2,009 $ 	1,776 $ 	1,111 $ 	5,701 $ 	10,598
Intersegment revenues 	378 	32 	18 	39 	467
2,387 	1,808 	1,129 	5,740 	11,065
Elimination of intersegment revenues 	(467)
Consolidated revenues 	$ 	10,598
Segment Income
Cost of revenues 	907 	878 	668 	4,488
Selling, general, and administrative expenses 	475 	310 	178 	588
Research and development expenses 	141 	134 	44 	16
Other segment items 	19 	35 	(54) 	(125)
Segment income 	845 	451 	293 	773 	2,362
Unallocated amounts
Cost of revenues adjustments 	(9)
Selling, general and administrative expenses adjustments 	(21)
Restructuring and other costs 	(45)
Amortization of acquisition-related intangible assets 	(450)
Interest income 	277
Interest expense 	(356)
Other income/(expense) 	(16)
Consolidated income before income taxes 	$ 	1,742
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	86,575 $ 	3,211 $ 	2,905 $ 	1,234 $ 	6,438 $ 	100,364
Purchases of property, plant and equipment 	23 	27 	19 	26 	177 	271
Depreciation of property, plant and equipment 	— 	58 	25 	29 	179 	291
23

-- 23 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2025
Nine months ended September 27, 2025
(In millions)
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	6,263 $ 	5,193 $ 	3,402 $ 	17,483 $ 	32,341
Intersegment revenues 	1,165 	145 	54 	122 	1,487
7,428 	5,339 	3,456 	17,605 	33,828
Elimination of intersegment revenues 	(1,487)
Consolidated revenues 	$ 	32,341
Segment Income
Cost of revenues 	2,742 	2,713 	2,001 	13,728
Selling, general, and administrative expenses 	1,406 	939 	529 	1,773
Research and development expenses 	408 	426 	134 	41
Other segment items 	150 	108 	(140) 	(362)
Segment income 	2,722 	1,153 	932 	2,425 	7,231
Unallocated amounts
Cost of revenues adjustments 	(31)
Selling, general and administrative expenses adjustments 	(99)
Restructuring and other costs 	(316)
Amortization of acquisition-related intangible assets 	(1,294)
Interest income 	735
Interest expense 	(1,054)
Other income/(expense) 	(18)
Consolidated income before income taxes 	$ 	5,155
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	88,209 $ 	3,552 $ 	3,189 $ 	1,307 $ 	6,763 $ 	103,020
Purchases of property, plant and equipment 	85 	101 	75 	92 	707 	1,060
Depreciation of property, plant and equipment 	— 	177 	76 	68 	439 	758
24

-- 24 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
2024
Nine months ended September 28, 2024
(In millions) Life Sciences
Solutions Analytical
Instruments Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Total
Revenues
Revenues from external customers 	$ 	5,935 $ 	5,132 $ 	3,310 $ 	17,106 $ 	31,484
Intersegment revenues 	1,092 	145 	45 	115 	1,397
7,027 	5,277 	3,355 	17,221 	32,881
Elimination of intersegment revenues 	(1,397)
Consolidated revenues 	$ 	31,484
Segment Income
Cost of revenues 	2,587 	2,529 	1,919 	13,493
Selling, general, and administrative expenses 	1,334 	933 	553 	1,768
Research and development expenses 	403 	405 	128 	50
Other segment items 	153 	121 	(130) 	(352)
Segment income 	2,551 	1,289 	886 	2,262 	6,987
Unallocated amounts
Cost of revenues adjustments 	(25)
Selling, general and administrative expenses adjustments 	24
Restructuring and other costs 	(151)
Amortization of acquisition-related intangible assets 	(1,514)
Interest income 	851
Interest expense 	(1,073)
Other income/(expense) 	(2)
Consolidated income before income taxes 	$ 	5,096
(In millions)
Unallocated
amounts
Life Sciences
Solutions
Analytical
Instruments
Specialty
Diagnostics
Laboratory
Products and
Biopharma
Services 	Consolidated
Segment assets 	$ 	86,575 $ 	3,211 $ 	2,905 $ 	1,234 $ 	6,438 $ 	100,364
Purchases of property, plant and equipment 	61 	78 	64 	79 	637 	920
Depreciation of property, plant and equipment 	— 	171 	76 	72 	534 	852
25

-- 25 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Note 12. Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill,
primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces.
These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of
the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company
products and services.
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying
financial statements from their respective dates of acquisition.
Pending Acquisition
The company has entered into an agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash at the closing of the transaction, with an
additional $125 million in deferred consideration and up to $400 million in contingent consideration to be payable following the closing. Clario is a leading
provider of endpoint data solutions for clinical trials. The transaction, which is expected to be completed by the middle of 2026, is subject to customary closing
conditions and regulatory approvals. Upon completion, Clario will become part of the Laboratory Products and Biopharma Services segment.
2025
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, Solventum Corporation’s Purification and Filtration business, which
became the company’s filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as
in medical technologies and industrial applications. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies that
improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into
industries including battery, semiconductor and medical device manufacturing. The goodwill recorded as a result of this business combination is not expected to be
tax deductible.
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions)
Filtration and
separation business
Purchase price
Cash paid 	$ 	3,944
Fair value of contingent consideration 	(65)
Cash acquired 	(9)
$ 	3,871
Net assets acquired
Property, plant and equipment 	$ 	411
Definite-lived intangible assets
Customer relationships 	1,114
Product technology 	387
Trade names 	51
Goodwill 	2,103
Net other assets/(liabilities) 	172
Deferred tax assets (liabilities) 	(366)
$ 	3,871
The preliminary allocation of the purchase price for the acquisition of Solventum’s Filtration and Separation business is based on the estimates of the fair value of
the purchase price and net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets, real and personal
property, inventory and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.
In addition, in 2025, the company acquired within the Laboratory Products and Biopharma Services segment, a sterile fill finishing and packaging facility to meet
the growing demand from pharma and biotech customers for U.S. manufacturing capacity.
26

-- 26 of 43 --

THERMO FISHER SCIENTIFIC INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
The weighted-average amortization periods for definite-lived intangible assets acquired in 2025 are 18 years for customer relationships, 19 years for product
technology, and 15 years for trade names. The weighted-average amortization period for all definite-lived intangible assets acquired in 2025 is 18 years.
2024
On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation
proteomics solutions. The acquisition enhances the segment’s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions.
It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy
opportunities. The goodwill recorded as a result of this business combination is not tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In millions) 	Olink
Purchase price
Cash paid 	$ 	3,215
Purchase price payable 	28
Cash acquired 	(97)
$ 	3,146
Net assets acquired
Definite-lived intangible assets
Customer relationships 	$ 	708
Product technology 	207
Trade names 	97
Goodwill 	2,301
Net other assets/(liabilities) 	9
Deferred tax assets (liabilities) 	(176)
$ 	3,146
The weighted-average amortization periods for definite-lived intangible assets acquired in 2024 are 19 years for customer relationships, 15 years for product
technology, and 15 years for trade names. The weighted-average amortization period for definite-lived intangible assets acquired in 2024 is 18 years.
27

-- 27 of 43 --

THERMO FISHER SCIENTIFIC INC.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this
Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any statements contained herein that are not statements of historical fact
may be deemed to be forward-looking statements, including without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates,
tax provisions, cash flows, pension and benefit obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new
product and service developments, competitive strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into;
new or modified laws, regulations and accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent
liabilities; foreign currency exchange rates and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing;
assumptions underlying any of the foregoing; and any other statements that address events or developments that Thermo Fisher intends or believes will or may
occur in the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are
intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to
update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not
rely on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this report.
A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those
detailed under the caption “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 (which is on file with the SEC).
Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to:
the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions
and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions,
impact of tariffs, and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental
regulations; any natural disaster, public health crisis, pandemic, or other catastrophic event; and the effect of laws and regulations governing government contracts,
as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These non-
GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later in this
“Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Certain amounts and percentages reported within this Quarterly Report on Form 10-Q are presented and calculated based on underlying unrounded amounts. As a
result, the sum of components may not equal corresponding totals due to rounding.
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex
analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing
therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The
company’s operations fall into four segments (Note 11): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and
Biopharma Services.
Consolidated Results
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(Dollars in millions except per share amounts) 	2025 	2024 	Change 	2025 	2024 	Change
Revenues 	$ 	11,122 	$ 	10,598 	5 % $ 	32,341 	$ 	31,484 	3 %
GAAP operating income 	1,941 	1,838 	6 % 	5,491 	5,321 	3 %
GAAP operating income margin 	17.4 % 	17.3 % 	0.1 pt 	17.0 % 	16.9 % 	0.1 pt
Adjusted operating income (non-GAAP measure) 	2,587 	2,362 	9 % 	7,231 	6,987 	3 %
Adjusted operating income margin (non-GAAP measure) 	23.3 % 	22.3 % 	1.0 pt 	22.4 % 	22.2 % 	0.2 pt
GAAP diluted earnings per share attributable to Thermo
Fisher Scientific Inc. 	4.27 	4.25 	0 % 	12.53 	11.75 	7 %
Adjusted earnings per share (non-GAAP measure) 	5.79 	5.28 	10 % 	16.30 	15.76 	3 %
28

-- 28 of 43 --

THERMO FISHER SCIENTIFIC INC.
Organic Revenue Growth
Three months ended 	Nine months ended
September 27, 2025 	September 27, 2025
Revenue growth 	5 % 	3 %
Impact of acquisitions 	1 % 	0 %
Impact of currency translation 	1 % 	0 %
Organic revenue growth (non-GAAP measure) 	3 % 	2 %
During the third quarter of 2025, revenues grew in the pharma and biotech market, driven by our trusted partner status with customers. Revenues in the academic
and government market declined, reflecting customer hesitancy in a more uncertain environment, which resulted in muted demand for equipment and instruments.
Revenues grew in the industrial and applied market due to strong demand for our innovative products serving this market. Revenue to customers in the diagnostics
and healthcare market declined as we navigated headwinds in China. During the third quarter of 2025, sales grew in North America. Sales growth was strong in
Europe and Asia-Pacific, despite weak economic activity in China. Contributions to organic revenue during the third quarter of 2025 were led by the Laboratory
Products and Biopharma Services and Life Sciences Solutions segments.
During the first nine months of 2025, revenues grew in the pharma and biotech market due to increased demand from customers, partially offset by reduced demand
for COVID-19 vaccine and therapy related products and services. Revenues in the academic and government market declined, driven by customer hesitancy in a
more uncertain environment in the U.S. and macro conditions in China. Revenue to customers in the industrial and applied market grew. Revenue to customers in
the diagnostics and healthcare market declined slightly. During the first nine months of 2025, sales grew in North America, Europe and Asia-Pacific, but declined in
China. Contributions to organic revenue during the first nine months of 2025 were led by the Laboratory Products and Biopharma Services and Life Sciences
Solutions segments.
The company continues to execute its proven growth strategy which consists of three pillars:
• High-impact innovation,
• Our trusted partner status with customers, and
• Our unparalleled commercial engine.
GAAP operating income margin and adjusted operating income margin increased in the third quarter of 2025 due primarily to very strong productivity
improvements, partially offset by strategic investments, the impact of tariffs and related foreign currency effects, and unfavorable business mix. GAAP operating
income margin in the third quarter of 2025 was also impacted by higher levels of restructuring and other charges incurred for headcount reductions and facility
consolidations in an effort to streamline operations (Note 6).
GAAP operating income margin and adjusted operating income margin increased the first nine months of 2025 due primarily to very strong productivity
improvements, partially offset by unfavorable business mix. GAAP operating income margin in the first nine months of 2025 benefited from lower amortization
expense when compared to 2024; however, this was partially offset by higher levels of restructuring and other charges incurred for headcount reductions and facility
consolidations in an effort to streamline operations (Note 6).
The company’s references to strategic investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of geographic
sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects and other
expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references throughout this
discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business system to address
inflation, including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure following
restructuring actions including headcount reductions and consolidation of facilities, and low cost region manufacturing.
Notable Recent Acquisitions
On July 10, 2024, the company acquired, within the Life Sciences Solutions segment, Olink Holding AB (publ), a Swedish-based provider of next-generation
proteomics solutions. The acquisition enhances the segment’s capabilities in the high-growth proteomics market with the addition of highly differentiated solutions.
It also complements the existing life sciences and mass spectrometry offerings, accelerating protein biomarker discovery and providing strong synergy
opportunities.
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, Solventum Corporation’s Purification and Filtration business, which
became the company’s filtration and separation business, a leading provider of
29

-- 29 of 43 --

THERMO FISHER SCIENTIFIC INC.
purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications. The business strengthens
the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In
addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 11 to the
Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2024. Accordingly, the following segment data are reported on this basis.
Three months ended 	Nine months ended
(Dollars in millions) 	September 27, 2025 	September 28, 2024 	September 27, 2025 	September 28, 2024
Revenues
Life Sciences Solutions 	$ 	2,588 $ 	2,387 $ 	7,428 $ 	7,027
Analytical Instruments 	1,893 	1,808 	5,339 	5,277
Specialty Diagnostics 	1,174 	1,129 	3,456 	3,355
Laboratory Products and Biopharma Services 	5,970 	5,740 	17,605 	17,221
Eliminations 	(503) 	(467) 	(1,487) 	(1,397)
Consolidated revenues 	$ 	11,122 $ 	10,598 $ 	32,341 $ 	31,484
Life Sciences Solutions
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	2,588 	$ 	2,387 	8 % 	3 % 	1 % 	5 %
Segment income 	968 	845 	15 %
Segment income margin 	37.4 % 	35.4 % 	2.0 pt
The increase in organic revenues in the third quarter of 2025 was primarily driven by the bioproduction business. On a reported basis, the bioproduction business
grew $137 million, which contributed 6 percentage points of reported growth in the segment, driven by higher demand from pharma and biotech customers, as well
as the impact from the 2025 acquisition of the filtration and separation business. The increase in segment income margin resulted primarily from very strong
productivity improvements and volume leverage, partially offset by unfavorable business mix, strategic investments, and the impact from the acquisition of the
filtration and separation business.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	7,428 	$ 	7,027 	6 % 	2 % 	0 % 	3 %
Segment income 	2,722 	2,551 	7 %
Segment income margin 	36.6 % 	36.3 % 	0.3 pt
The increase in organic revenues in the first nine months of 2025 was driven by the bioproduction business. On a reported basis, the bioproduction business grew
$331 million, driven by higher demand from pharma and biotech customers, as well as the impact from the 2025 acquisition of the filtration and separation
business. Genetic sciences grew $75 million, driven by the 2024 acquisition of Olink. The increase in segment income margin resulted primarily from very strong
productivity improvements, partially offset by unfavorable business mix and the impact from the acquisitions of Olink and the filtration and separation business.
30

-- 30 of 43 --

THERMO FISHER SCIENTIFIC INC.
Analytical Instruments
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	1,893 	$ 	1,808 	5 % 	0 % 	1 % 	4 %
Segment income 	429 	451 	(5) %
Segment income margin 	22.6 % 	24.9 % 	(2.3) pt
The increase in organic revenues in the third quarter of 2025 was driven by the electron microscopy and chromatography and mass spectrometry businesses. On a
reported basis, the electron microscopy and chromatography and mass spectrometry businesses grew $58 million and $39 million, respectively, which contributed 3
percentage points and 2 percentage points, respectively, of reported growth in the segment. The decrease in segment income margin was driven by the impacts of
tariffs and related foreign exchange. Additionally, strong productivity was more than offset by strategic investments and unfavorable business mix.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	5,339 	$ 	5,277 	1 % 	0 % 	0 % 	1 %
Segment income 	1,153 	1,289 	(11) %
Segment income margin 	21.6 % 	24.4 % 	(2.8) pt
The increase in organic revenues in the first nine months of 2025 was primarily due to growth in the electron microscopy business, partially offset by declines in the
chemical analysis business. On a reported basis, the electron microscopy business grew $105 million, partially offset by a decline of $78 million in the chemical
analysis business. The decrease in segment income margin resulted primarily from the impacts of tariffs and related foreign exchange, unfavorable volume mix, and
strategic investments, partially offset by strong pricing realization.
Specialty Diagnostics
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	1,174 	$ 	1,129 	4 % 	0 % 	2 % 	2 %
Segment income 	321 	293 	10 %
Segment income margin 	27.4 % 	25.9 % 	1.5 pt
The increase in organic revenues in the third quarter of 2025 was driven by growth in the immunodiagnostics and transplant diagnostics businesses. On a reported
basis, the immunodiagnostics and clinical diagnostics businesses grew $18 million and $17 million, respectively, each of which contributed 2 percentage points of
reported growth in the segment. The increase in segment income margin was principally driven by strong productivity and volume leverage.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	3,456 	$ 	3,355 	3 % 	0 % 	1 % 	2 %
Segment income 	932 	886 	5 %
Segment income margin 	27.0 % 	26.4 % 	0.6 pt
The increase in organic revenues in the first nine months of 2025 was driven by growth in the healthcare market channel and the transplant diagnostics business. On
a reported basis, the immunodiagnostics business grew $32 million, the transplant diagnostics business grew $31 million, and the healthcare market channel grew
$23 million, which were the principal drivers of reported revenue growth in the segment. The increase in segment income margin was due to strong pricing
realization, partially offset by unfavorable business mix.
31

-- 31 of 43 --

THERMO FISHER SCIENTIFIC INC.
Laboratory Products and Biopharma Services
Three months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	5,970 	$ 	5,740 	4 % 	0 % 	1 % 	3 %
Segment income 	868 	773 	12 %
Segment income margin 	14.5 % 	13.5 % 	1.0 pt
The increase in organic revenues in the third quarter of 2025 was primarily due to strong growth in the research and safety market channel, partially offset by
moderation in COVID-19 related revenue. On a reported basis, the research and safety market channel, pharma services business, and clinical research business
grew $122 million, $75 million, and $64 million, respectively, which contributed 2 percentage points, 1 percentage point, and 1 percentage point, respectively, of
reported growth in the segment. Segment income margin increased in the third quarter of 2025, with very strong productivity improvements, partially offset by
unfavorable business mix.
Nine months ended
Organic (non-
GAAP measure)	(Dollars in millions)
September 27,
2025
September 28,
2024
Total
Change
Acquisitions/
Divestitures
Currency
Translation
Revenues 	$ 	17,605 	$ 	17,221 	2 % 	0 % 	0 % 	2 %
Segment income 	2,425 	2,262 	7 %
Segment income margin 	13.8 % 	13.1 % 	0.7 pt
The increase in organic revenues in the first nine months of 2025 was primarily due to growth in the research and safety market channel and the pharma services
business, partially offset by moderation in COVID-19 related revenue. On a reported basis, the pharma services business and research and safety market channel
grew $271 million and $246 million, respectively. The increase in segment income margin was primarily due to exceptionally strong productivity improvements,
partially offset by unfavorable business mix and strategic investments.
Non-operating Items
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(Dollars and shares in millions) 	2025 	2024 	2025 	2024
Net interest expense 	$ 	113 	$ 	80 	$ 	319 	$ 	223
GAAP other income/(expense) 	(2) 	(16) 	(18) 	(2)
Adjusted other income/(expense) (non-GAAP measure) 	(7) 	(13) 	(19) 	(10)
GAAP tax rate 	11.3 % 	5.7 % 	7.6 % 	10.0 %
Adjusted tax rate (non-GAAP measure) 	11.0 % 	10.5 % 	10.4 % 	10.3 %
Weighted average diluted shares 	378 	384 	378 	383
Net interest expense (interest expense less interest income) in the third quarter and first nine months of 2025 increased due primarily to lower cash, and cash
equivalents and short-term investments balances, as well as lower interest rates on these balances when compared to the third quarter and first nine months of 2024.
In the third quarter and first nine months of 2025, the company’s net interest expense was reduced by approximately $66 million and $199 million, respectively, as a
result of its interest rate swap and cross-currency interest rate swap arrangements. In the third quarter and first nine months of 2024, the company’s net interest
expense was reduced by approximately $66 million and $197 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap
arrangements (Note 10).
GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities, and
net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in the third quarter and first nine months of 2025
also includes $7 million and $9 million, respectively, of net gains on investments, and $2 million and $8 million, respectively, of settlement charges for pension
plans. GAAP other income/(expense) in the third quarter and first nine months of 2024 also includes $(3) million and $7 million, respectively, of net gains/(losses)
on investments.
The company’s GAAP and adjusted tax rates in the third quarter of 2025 were impacted by an $86 million tax benefit from tax return reassessments. The company’s
GAAP tax rate in the third quarter of 2025 was also impacted by tax legislation enacted during the quarter (Note 7).
32

-- 32 of 43 --

THERMO FISHER SCIENTIFIC INC.
The company’s GAAP and adjusted tax rates in the first nine months of 2025 were impacted by a $125 million deferred tax benefit resulting from the recognition of
a tax attribute related to a domestication transaction, a deferred tax benefit of $153 million related to capital losses generated as part of intra-entity transactions, a
$93 million benefit in jurisdictions where the deferred tax assets are now expected to be realized due to forecasted income, and an $86 million tax benefit from tax
return reassessments (Note 7).
The company’s GAAP and adjusted tax rates in the first nine months of 2024 were impacted by $176 million of expense, net, for a provision associated with a tax
audit recorded in the first quarter of 2024. The company’s GAAP and adjusted tax rates in the first nine months of 2024 were also impacted by tax benefits of $183
million and $124 million, in the second and third quarters of 2024, respectively, primarily in jurisdictions where the deferred tax assets are now expected to be
realized due to forecasted income. The company’s GAAP and adjusted tax rates in the first nine months of 2024 were also impacted by $102 million of tax benefits
resulting from capital losses generated as part of intra-entity transactions (Note 7).
The effective tax rates in both 2025 and 2024 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-deductibility
of intangible asset amortization for tax purposes, the company’s cash payments for income taxes are higher than its income tax expense for financial reporting
purposes and are expected to total approximately $1.70 billion in 2025.
The company expects its GAAP effective tax rate in 2025 will be between 8% and 10% based on currently forecasted rates of profitability in the countries in which
the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a result of
discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 10.5% in 2025.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S. The
company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on the
statutory tax rates in those countries. Based on the dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a
change in the statutory tax rate in any individual country is not likely to materially affect the company’s income tax provision or net income.
Equity in earnings/losses of unconsolidated entities was impacted by an $88 million impairment of an equity method investment in the second quarter of 2024.
Weighted average diluted shares decreased in 2025 compared to 2024, primarily due to share repurchases.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital primarily via
mergers and acquisitions and secondarily via share buybacks and dividends.
(In millions) 	September 27, 2025 	December 31, 2024
Cash and cash equivalents 	$ 	1,982 	$ 	4,009
Short-term investments 	1,564 	1,561
Total debt 	35,681 	31,275
Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs outside
of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also transfers
cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S. dividend received
deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the U.S., the company does not
expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its
revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24
months.
As of September 27, 2025, the company’s short-term obligations and current maturities of long-term obligations totaled $3.82 billion. The company has a revolving
credit facility with a bank group that provides up to $5.00 billion of unsecured multi-currency revolving credit (Note 3). If the company borrows under this facility,
it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not
available. As of September 27, 2025, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by
immaterial outstanding letters of credit.
33

-- 33 of 43 --

THERMO FISHER SCIENTIFIC INC.
Nine months ended
(In millions) 	September 27, 2025 	September 28, 2024
Net cash provided by operating activities 	$ 	4,361 	$ 	5,377
Net cash used in investing activities 	(4,938) 	(5,861)
Net cash used in financing activities 	(1,725) 	(3,126)
Free cash flow (non-GAAP measure) 	3,319 	4,498
Operating Activities
During the first nine months of 2025, cash provided by income was offset in part by investments in working capital. Changes in other assets and liabilities used cash
of $1.21 billion primarily due to the timing of payments for compensation and income taxes. Cash payments for income taxes were $1.60 billion during the first
nine months of 2025.
During the first nine months of 2024, cash provided by income was offset in part by investments in working capital. An increase in inventories used cash of $0.22
billion. A decrease in accounts payable used cash of $0.24 billion. Changes in other assets and liabilities used cash of $0.24 billion primarily due to the timing of
payments for compensation and income taxes. Cash payments for income taxes were $1.43 billion during the first nine months of 2024.
Investing Activities
During the first nine months of 2025, acquisitions used cash of $4.04 billion. The company’s investing activities also included purchases of $1.06 billion for the
purchase of property, plant and equipment for capacity and capability investments.
During the first nine months of 2024, acquisitions used cash of $3.13 billion. The company’s investing activities also included purchases of short-term investments
of $2.07 billion, as well as $0.92 billion of purchases of property, plant and equipment for capacity and capability investments.
The company expects that for all of 2025, expenditures for property, plant and equipment, net of disposals, will be between $1.4 billion and $1.7 billion.
Financing Activities
During the first nine months of 2025, issuance of debt and net commercial paper activity provided $3.34 billion of cash. Repayment of debt used cash of $1.63
billion. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (2.1 million shares), of which $0.04
billion settled in the fourth quarter of 2025, and the payment of $0.47 billion in cash dividends. On November 15, 2024, the Board of Directors announced that it
replaced the existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to
$4.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during the first nine months of 2025 were under this
program, depleting the 2024 authorization.
In the fourth quarter of 2025, the company issued $2.50 billion of senior notes (Note 3).
During the first nine months of 2024, issuance of debt provided $1.20 billion of cash. Repayment of senior notes used $1.11 billion. The company’s financing
activities also included the repurchase of $3.00 billion of the company’s common stock (5.5 million shares) and the payment of $0.43 billion in cash dividends.
The company’s commitments for purchases of property, plant and equipment, contractual obligations and other commercial commitments, did not change materially
subsequent to December 31, 2024, except in connection with the completion of the filtration and separation business acquisition, which occurred on September 1,
2025, as well as the agreement to acquire Clario Holdings, Inc. (Note 12).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures
such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the effects of currency
translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-term and long-term
financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues. Thermo Fisher management
uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues of current periods to prior
periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that the
use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and
future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to
34

-- 34 of 43 --

THERMO FISHER SCIENTIFIC INC.
previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-
making and for compensation purposes. To calculate these measures we exclude, as applicable:
• Certain transaction-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction-related third-party
costs, changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for
pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
• Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating
facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are not
indicative of our normal operating costs.
• Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot
be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant
litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of
our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
• The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions
may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that
are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
• The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from
enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for
future periods.
We report free cash flow, which is operating cash flow less net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use
in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is
not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from
the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-Q are not meant to be considered superior to or a
substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most directly
comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(Dollars in millions except per share amounts) 	2025 	2024 	2025 	2024
Reconciliation of adjusted operating income
GAAP operating income 	$ 	1,941 	$ 	1,838 	$ 	5,491 	$ 	5,321
Cost of revenues adjustments (a) 	10 	9 	31 	25
Selling, general and administrative expenses adjustments (b) 	66 	21 	99 	(24)
Restructuring and other costs (c) 	135 	45 	316 	151
Amortization of acquisition-related intangible assets 	435 	450 	1,294 	1,514
Adjusted operating income (non-GAAP measure) 	$ 	2,587 	$ 	2,362 	$ 	7,231 	$ 	6,987
Reconciliation of adjusted operating income margin
GAAP operating income margin 	17.4 % 	17.3 % 	17.0 % 	16.9 %
Cost of revenues adjustments (a) 	0.1 % 	0.1 % 	0.1 % 	0.1 %
Selling, general and administrative expenses adjustments (b) 	0.6 % 	0.2 % 	0.3 % 	(0.1)%
Restructuring and other costs (c) 	1.2 % 	0.4 % 	1.0 % 	0.5 %
Amortization of acquisition-related intangible assets 	3.9 % 	4.2 % 	4.0 % 	4.8 %
Adjusted operating income margin (non-GAAP measure) 	23.3 % 	22.3 % 	22.4 % 	22.2 %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense) 	$ 	(2) 	$ 	(16) 	$ 	(18) 	$ 	(2)
Adjustments (d) 	(5) 	3 	(1) 	(8)
Adjusted other income/(expense) (non-GAAP measure) 	$ 	(7) 	$ 	(13) 	$ 	(19) 	$ 	(10)
35

-- 35 of 43 --

THERMO FISHER SCIENTIFIC INC.
Three months ended 	Nine months ended
September 27, 	September 28, 	September 27, 	September 28,
(Dollars in millions except per share amounts) 	2025 	2024 	2025 	2024
Reconciliation of adjusted tax rate
GAAP tax rate 	11.3 % 	5.7 % 	7.6 % 	10.0 %
Adjustments (e) 	(0.3)% 	4.8 % 	2.7 % 	0.3 %
Adjusted tax rate (non-GAAP measure) 	11.0 % 	10.5 % 	10.4 % 	10.3 %
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific
Inc. 	$ 	4.27 	$ 	4.25 	$ 	12.53 	$ 	11.75
Cost of revenues adjustments (a) 	0.03 	0.02 	0.08 	0.07
Selling, general and administrative expenses adjustments (b) 	0.17 	0.05 	0.26 	(0.06)
Restructuring and other costs (c) 	0.36 	0.12 	0.83 	0.39
Amortization of acquisition-related intangible assets 	1.15 	1.17 	3.42 	3.95
Other income/expense adjustments (d) 	(0.01) 	0.01 	0.00 	(0.02)
Income taxes adjustments (e) 	(0.17) 	(0.36) 	(0.85) 	(0.50)
Equity in earnings/losses of unconsolidated entities 	(0.01) 	0.04 	0.02 	0.20
Noncontrolling interests adjustments (f) 	0.00 	(0.02) 	0.00 	(0.02)
Adjusted EPS (non-GAAP measure) 	$ 	5.79 	$ 	5.28 	$ 	16.30 	$ 	15.76
Reconciliation of free cash flow
GAAP net cash provided by operating activities 	$ 	2,239 	$ 	2,167 	$ 	4,361 	$ 	5,377
Purchases of property, plant and equipment 	(404) 	(271) 	(1,060) 	(920)
Proceeds from sale of property, plant and equipment 	5 	20 	17 	40
Free cash flow (non-GAAP measure) 	$ 	1,840 	$ 	1,915 	$ 	3,319 	$ 	4,498
(a) Adjusted results exclude accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations and charges for the sale of inventory revalued at the date of
acquisition. Adjusted results in the first nine months of 2024 also exclude $13 million of charges for inventory write-downs associated with large-scale abandonment of product lines.
(b) Adjusted results exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent
acquisition consideration, and charges associated with product liability litigation.
(c) Adjusted results exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other
matters, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in the third quarter and first nine months of 2025 also exclude
$51 million of charges for disposition of a consolidated joint venture.
(d) Adjusted results exclude net gains/losses on investments. Adjusted results in the first nine months of 2025 also exclude $8 million of settlement charges for pension plans.
(e) Adjusted results exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax
impacts from audit settlements.
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.
Critical Accounting Policies and Estimates
Management’s Discussion and Analysis and Note 1 to the Consolidated Financial Statements of the company’s Annual Report on Form 10-K for 2024 describe the
significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no significant changes in the company’s
critical accounting policies during the first nine months of 2025.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the
company’s Annual Report on Form 10-K for the year ended December 31, 2024.
36

-- 36 of 43 --

THERMO FISHER SCIENTIFIC INC.
Item 4. Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the
company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period
covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the company’s disclosure
controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal
quarter ended September 27, 2025, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial reporting.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 5 to our
Condensed Consolidated Financial Statements under the heading “Commitments and Contingencies.”
Item 1A. Risk Factors
The risks that we believe are material to our investors are discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2024, under
the caption “Risk Factors,” which is on file with the SEC.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
A summary of the share repurchase activity for the company’s third quarter of 2025 follows:
Period
Total number of
shares purchased
Average price
paid per share (1)
Total number of shares
purchased as part of
publicly announced plans or
programs (2)
Maximum dollar amount of
shares that may yet be
purchased under the plans or
programs (1)(2)
(in millions)
Fiscal July (Jun. 29 - Aug. 2) 	— 	$ 	— 	— 	$ 	1,000
Fiscal August (Aug. 3 - Aug. 30) 	— 	— 	— 	1,000
Fiscal September (Aug. 31 - Sep. 27) 	2,116,219 	472.54 	2,116,219 	—
Total third quarter 	2,116,219 	$ 	472.54 	2,116,219 	$ 	—
(1) Amounts exclude excise taxes and other transaction costs.
(2) On November 15, 2024, the Board of Directors announced that it replaced the existing authorization to repurchase the company’s common stock, of which $1.00 billion was
remaining, with a new authorization to repurchase up to $4.00 billion of the company’s common stock. All of the shares of common stock repurchased by the company during
the third quarter of 2025 were under this program, depleting the 2024 authorization.
Item 5. Other Information
Director and Officer Trading Arrangements
During the three months ended September 27, 2025, no director or executive officer of the company adopted, modified or terminated a “Rule 10b5-1 trading
arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as provided below:
Name and Title 	Action 	Plan Type
Date of adoption
of Rule 10b5-1
trading plan
Scheduled
expiration of Rule
10b5-1 trading plan
Aggregate number of
securities to be
purchased or sold
Frederick Lowery, Executive Vice President 	Adoption 	Rule 10b5-1 	8/28/2025 	2/27/2026 	13,825
Gianluca Pettiti, Executive Vice President 	Adoption 	Rule 10b5-1 	9/12/2025 	7/28/2026 	4,175
37

-- 37 of 43 --

THERMO FISHER SCIENTIFIC INC.
Item 6. Exhibits
Exhibit
Number 	Description of Exhibit
31.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
31.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.
32.1 	Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002.**
32.2 	Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.**
101.INS 	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL
document.
101.SCH 	XBRL Taxonomy Extension Schema Document.
101.CAL 	XBRL Taxonomy Calculation Linkbase Document.
101.DEF 	XBRL Taxonomy Definition Linkbase Document.
101.LAB 	XBRL Taxonomy Label Linkbase Document.
101.PRE 	XBRL Taxonomy Presentation Linkbase Document.
104 	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect to
long-term debt of the Registrant or its consolidated subsidiaries.
_______________________
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be
incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
38

-- 38 of 43 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: 	October 31, 2025 	THERMO FISHER SCIENTIFIC INC.
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer
/s/ Joseph R. Holmes
Joseph R. Holmes
Vice President and Chief Accounting Officer
39

-- 39 of 43 --

Exhibit 31.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marc N. Casper, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: October 31, 2025
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer

-- 40 of 43 --

Exhibit 31.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen Williamson, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and
have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s
auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: October 31, 2025
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer

-- 41 of 43 --

Exhibit 32.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended September 27, 2025 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman, President and Chief Executive
Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: October 31, 2025
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be
retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 42 of 43 --

Exhibit 32.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Thermo Fisher Scientific Inc. (the “Company”) for the period ended September 27, 2025 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief Financial
Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: October 31, 2025
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and will be
retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

-- 43 of 43 --